NDT Pharmaceuticals Inc (NDTP)

[Ecomike]

Furthermore,

https://www.healthline.com/nutrition/egcg-epigallocatechin-gallate#dosage-and-side-effects

Enter the need for liposomal EGCG-extract!

Dosage and possible side effects

Although EGCG has been studied for decades, its physical effects are quite varied.

Some experts believe this may be because EGCG easily degrades in the presence of oxygen, and many people don’t absorb it efficiently in the digestive tract (16Trusted Source).

The reason for this is not completely understood, but it may be related to the fact that a lot of EGCG bypasses the small intestine too quickly and ends up being degraded by bacteria in the large intestine (16Trusted Source).

And,

https://www.thno.org/v08p5469.htm

"Parkinson's disease (PD) is arguably one of the most recognizable brain disorders and is a growing concern in the modern world [1,2]. The majority of the currently available treatments for PD are dopamine replacement therapies that are not suitable for long-term use"

"Epigallocatechin gallate (EGCG), a safe and cheap compound, can prevent aS aggregation in vitro [5-7]. Additionally, EGCG reduces the loss of dopaminergic neurons in the SN and prevents tyrosine hydroxylase (TH) protein depletion in vivo [8]. Regrettably, there are many challenges in the targeting of EGCG to its acting site. It is difficult to accumulate EGCG in the brain due to the blood-brain barrier (BBB).

Importantly, EGCG cannot be internalized into dopaminergic neurons as a result of its high binding affinities with some membrane proteins [9-11]. These high binding affinities can hijack EGCG and hinder endocytosis. Moreover, the accumulation of EGCG cannot be evaluated during treatments. Therefore, the key to successful PD treatment lies in visualizing EGCG accumulation in dopaminergic neurons.

Nanoparticles (NPs) have the potential to overcome these shortcomings. One target molecule B6, a representative peptide with high affinity for transferrin receptor (TfR) on the BBB, can be conjugated to the surface of NPs to facilitate their entry into the brain [12,13].

Dopamine transporter (DAT), expressed on dopaminergic neurons specifically, can be chosen as the NPs' target. Mazindol (MA) is a potent inhibitor of DA uptake, as it promotes DAT internalization. It has the same binding site as cocaine, but the binding affinity of MA to DAT is 11-fold higher than that of cocaine. It is considered an attractive molecular target for the development of novel drug abuse treatments [14-16]. Hence, the “MA-DAT” model can be used for intracellular delivery, similar to the “cocaine-DAT” mechanism of addiction. Therefore, MA was conjugated on the surface of the NPs and innovative cell-addictive NPs were developed. The reactive oxygen species (ROS)-labile boronate ester was used as a linker between DSPE-PEG2000 and EGCG, because the dopaminergic neurons maintain high ROS status in PD patients."